Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 178-185 , July 2010

The Treatment of Early-Stage Disease

  • Clifford G. Robinson, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Clifford G. Robinson, MD, Siteman Cancer Center, Center for Advanced Medicine, 4921 Parkview Place, St. Louis, MO 63110
    • ,
  • Jeffrey D. Bradley, MD

References 

  1. Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society; 2009;
  2. Groome PA, Bolejack V, Crowley JJ. The IASLC lung cancer staging project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:694–705
  3. Wilson DO, Weissfeld JL, Fuhrman CR. The Pittsburgh Lung Screening Study (PLuSS): Outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med. 2008;178:956–961
  4. Goldstraw P, Crowley J, Chansky K. The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–714
  5. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology, 2009. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdfAccessed September 20, 2009
  6. BTS. Guidelines: Guidelines on the selection of patients with lung cancer for surgery. Thorax. 2001;56:89–108
  7. Colice GL, Shafazand S, Griffin JP. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:161S–177S
  8. Myrdal G, Gustafsson G, Lambe M. Outcome after lung cancer surgery (Factors predicting early mortality and major morbidity). Eur J Cardio Thorac Surg. 2001;20:694–699
  9. Goodney PP, Lucas FL, Stukel TA. Surgeon specialty and operative mortality with lung resection. Ann Surg. 2005;241:179–184
  10. Rami-Porta R, Ball D, Crowley J. The IASLC lung cancer staging project: Proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2:593–602
  11. Cerfolio RJ, Bryant AS. Survival of patients with true pathologic stage I non-small cell lung cancer. Ann Thorac Surg. 2009;88:917–922
  12. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998;352:257–263
  13. Lally BE, Zelterman D, Colasanto JM. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006;24:2998–3006
  14. Douillard JY, Rosell R, De Lena M. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant Navelbine International Trialist Association [Anita]): A randomised controlled trial. Lancet Oncol. 2006;7:719–727
  15. Douillard JY, Rosell R, De Lena M. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys. 2008;72:695–701
  16. Trodella L, Granone P, Valente S. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: Definitive results of a phase III randomized trial. Radiother Oncol. 2002;62:11–19
  17. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2005;CD:002142
  18. Kelsey CR, Marks LB, Hollis D. Local recurrence after surgery for early stage lung cancer: An 11-year experience with 975 patients. Cancer. 2009;115:5218-1527
  19. Choong CK, Meyers BF, Battafarano RJ. Lung cancer resection combined with lung volume reduction in patients with severe emphysema. J Thorac Cardiovasc Surg. 2004;127:1323–1331
  20. Linden PA, Bueno R, Colson YL. Lung resection in patients with preoperative FEV1 <35% predicted. Chest. 2005;127:1984–1990
  21. Shennib H, Bogart J, Herndon JE. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: The Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional Cooperative Group study. J Thorac Cardiovasc Surg. 2005;129:813–818
  22. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer (Lung Cancer Study Group). Ann Thorac Surg. 1995;60:615–622
  23. Sugi K, Kobayashi S, Sudou M. Long-term prognosis of video-assisted limited surgery for early lung cancer. Eur J Cardiothorac Surg. 2009;37:456–460
  24. Phase III randomized study of lobectomy versus sublobar resection in patients with small peripheral stage IA non-small cell. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=555324&version=HealthProfessional&protocolsearchid=6789389Accessed September 20, 2009
  25. Voynov G, Heron DE, Lin CJ. Intraoperative (125)I VICRYL Mesh brachytherapy after sublobar resection for high-risk stage I non-small cell lung cancer. Brachytherapy. 2005;4:278–285
  26. Santos R, Colonias A, Parda D. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with stage I non-small-cell lung cancer. Surgery. 2003;134:691–697
  27. Lee W, Daly BD, DiPetrillo TA. Limited resection for non-small cell lung cancer: Observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg. 2003;75:237–242
  28. Phase III randomized study of sublobar resection with versus without intraoperative brachytherapy in high-risk patients with stage I non-small cell. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=422346&version=HealthProfessional&protocolsearchid=6765732Accessed September 20, 2009
  29. Winton T, Livingston R, Johnson D. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597
  30. Arriagada R, Bergman B, Dunant A. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360
  31. Waller D, Peake MD, Stephens RJ. Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur J Cardio Thorac Surg. 2004;26:173–182
  32. Scagliotti GV, Fossati R, Torri V. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst. 2003;95:1453–1461
  33. Pignon JP, Tribodet H, Scagliotti GV. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–3559
  34. Strauss G, Maddaus M, Johnstone D. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage Ib non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol (Meeting Abstracts). 2004;22:7019
  35. Strauss GM, Herndon JE, Maddaus MA. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol. 2008;26:5043–5051
  36. Goodgame B, Viswanathan A, Zoole J. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol. 2009;4:1370–1374
  37. Chen HY, Yu SL, Chen CH. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356:11–20
  38. Potti A, Mukherjee S, Petersen R. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006;355:570–580
  39. Phase III randomized study of adjuvant chemotherapy versus observation in patients with stage I non-small cell. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=636895&version=HealthProfessional&protocolsearchid=6769410Accessed September 20, 2009
  40. Bach PB, Cramer LD, Warren JL. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341:1198–1205
  41. McGarry RC, Song G, des Rosiers P. Observation-only management of early stage, medically inoperable lung cancer: Poor outcome. Chest. 2002;121:1155–1158
  42. Raz DJ, Zell JA, Ou SH. Natural history of stage I non-small cell lung cancer: Implications for early detection. Chest. 2007;132:193–199
  43. Werner-Wasik M, Xiao Y, Pequignot E. Assessment of lung cancer response after nonoperative therapy: Tumor diameter, bidimensional product, and volume (A serial CT scan-based study). Int J Radiat Oncol Biol Phys. 2001;51:56–61
  44. Qiao X, Tullgren O, Lax I. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41:1–11
  45. Chen M, Hayman JA, ten Haken RK. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: Is low incidence of regional failure due to incidental nodal irradiation?. Int J Radiat Oncol Biol Phys. 2006;64:120–126
  46. Hayman JA, Martel MK, ten Haken RK. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial. J Clin Oncol. 2001;19:127–136
  47. Bradley J, Graham MV, Winter K. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:318–328
  48. Rosenzweig KE, Fox JL, Yorke E. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005;103:2118–2127
  49. Bogart J, Watson D, Seagren S. Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study. J Clin Oncol (Meeting Abstracts). 2007;25:7556
  50. Radiation therapy in treating patients with stage I or stage II non-small cell lung cancer that cannot Be removed by surgery. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=652051&version=HealthProfessional&protocolsearchid=6789406Accessed September 20, 2009
  51. Phase II study of hypofractionated 3-dimensional conformal radiotherapy in patients with newly diagnosed stage I-III non-small cell. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=639199&version=HealthProfessional&protocolsearchid=6784955Accessed September 20, 2009
  52. Sulman EP, Komaki R, Klopp AH. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiol Oncol. 2009;4:5
  53. Bradley JD, Wahab S, Lockett MA. Elective nodal failures are uncommon in medically inoperable patients with stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys. 2003;56:342–347
  54. Zhao L, Chen M, ten Haken R. Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol. 2007;82:153–159
  55. Carey SM, Katz A, Constine LS. Stereotactic body radiation therapy for extracranial oligometastases: Does the sword have a double edge?. Semin Radiat Oncol. 2006;16:67–76
  56. Brock J, Ashley S, Bedford J. Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer. Clin Oncol R Coll Radiol. 2008;20:666–676
  57. Lagerwaard FJ, Haasbeek CJ, Smit EF. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:685–692
  58. Baumann P, Nyman J, Hoyer M. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer—A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008;88:359–367
  59. Koto M, Takai Y, Ogawa Y. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85:429–434
  60. Takeda A, Sanuki N, Kunieda E. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys. 2009;73:442–448
  61. Timmerman R, McGarry R, Yiannoutsos C. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839
  62. Timmerman R, Papiez L, McGarry R. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946–1955
  63. Timmerman RD, Paulus R, Galvin J: Stereotactic body radiation therapy for medically inoperable early-stage lung cancer patients: Analysis of RTOG 0236: Presented at the 51st Annual Meeting of the American Society for Radiation Oncology. Chicago, IL, 2009
  64. Nagata Y, Hiraoka M, Mizowaki T. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys. 2009;75:343–347
  65. Hara R, Itami J, Kondo T. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer. 2006;106:1347–1352
  66. Hof H, Muenter M, Oetzel D. Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC). Cancer. 2007;110:148–155
  67. Phase II randomized study of single fraction versus multiple fraction stereotactic body radiotherapy in medically inoperable patients with stage I peripheral non-small cell. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=652101&version=HealthProfessional&protocolsearchid=6830553Accessed September 20, 2009
  68. Onishi H, Shirato H, Nagata Y. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2:S94–S100
  69. Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 2008;18:240–243
  70. Brenner DJ. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol. 2008;18:234–239
  71. Park C, Papiez L, Zhang S. Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:847–852
  72. Flickinger JC, Kondziolka D, Maitz AH. An analysis of the dose–response for arteriovenous malformation radiosurgery and other factors affecting obliteration. Radiother Oncol. 2002;63:347–354
  73. Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell. 2005;8:89–91
  74. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: Models and concepts. Annu Rev Med. 2007;58:267–284
  75. Ch'ang HJ, Maj JG, Paris F. ATM regulates target switching to escalating doses of radiation in the intestines. Nat Med. 2005;11:484–490
  76. Phase I/II study of stereotactic body radiotherapy in medically inoperable patients with centrally located stage I non-small cell. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=613524&version=HealthProfessional&protocolsearchid=6830592Accessed September 20, 2009
  77. Gay HA, Sibata CH, Allison RR. Isodose-based methodology for minimizing the morbidity and mortality of thoracic hypofractionated radiotherapy. Radiother Oncol. 2009;91:369–378
  78. Milano MT, Constine LS, Okunieff P. Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiol Oncol. 2008;3:36
  79. Forquer JA, Fakiris AJ, Timmerman RD. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: Dose-limiting toxicity in apical tumor sites. Radiother Oncol. 2009;93:408–413
  80. Borst GR, Ishikawa M, Nijkamp J. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol. 2009;91:307–313
  81. Ricardi U, Filippi AR, Guarneri A. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. Acta Oncol. 2009;48:571–577
  82. Dunlap NE, Cai J, Biedermann GB. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009;76:796–801
  83. Stephans KL, Djemil T, Tendulkar RD: Prediction of chest wall toxicity after lung stereotactic body radiotherapy (SBRT): Presented at the 51st Annual Meeting of the American Society for Radiation Oncology. Chicago, IL, November 1-5, 2009
  84. Pettersson N, Nyman J, Johansson KA. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: A dose- and volume-response analysis. Radiother Oncol. 2009;91:360–368
  85. Uematsu M, Shioda A, Suda A. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–670
  86. Denlinger C, Bradley JD, El Naqa IM: Propensity matched comparison of surgery vs. stereotactic body radiation therapy in early stage lung cancer: Presented at the 89th Annual Meeting of the American Association for Thoracic Surgery. Boston, MA, May 9-13, 2009
  87. Phase II study of stereotactic body radiotherapy in patients with resectable stage I or II non-small cell. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=571744&version=HealthProfessional&protocolsearchid=6811460Accessed September 20, 2009
  88. Trial of either surgery or stereotactic radiotherapy for early stage (IA). http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=597713&version=HealthProfessional&protocolsearchid=6784945Accessed September 20, 2009
  89. International randomized study to compare CyberKnife stereotactic radiotherapy with surgical resection in stage I non-small cell. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=635570&version=HealthProfessional&protocolsearchid=6784945Accessed September 20, 2009

PII: S1053-4296(10)00012-3

doi: 10.1016/j.semradonc.2010.01.004

Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 178-185 , July 2010

Article Tools